Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP & Chief Strategy Officer | September 22, 2018 | September 25, 2018 |
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Chief Business Officer | September 10, 2025 | September 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date September 22, 2018 · Filed September 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 243,966 |
Reported balance
After 2018-09-22 transaction · row 1
1 source rowRow 1 · 2018-09-22 · Tax withholding · Disposed 22,158 · Balance 243,966 F1: Shares withheld to cover tax obligation from settlement of vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to cover tax obligation from settlement of vested restricted stock units.
LB PHARMACEUTICALS INC
Report date September 10, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.84 · Expires 2035-02-10 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-10 · Disposition to issuer · Disposed 26,893 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2035-02-10 | Direct | 26,893 |
Reported balance
After 2025-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-09-10 · Grant · Acquired 26,893 · Balance 26,893 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2035-09-09 | Direct | 229,860 |
Reported balance
After 2025-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-10 · Grant · Acquired 229,860 · Balance 229,860 F3: One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
F3: One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Surrozen, Inc./DE
Report date August 11, 2021 · Filed August 13, 2021
Section 16 reporting ended · disclosed 2021-08-13. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 229,860 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024443 · form4-09122025_060903.xml · derivative · entry 3 Soffer Gad · CIK 0001612090 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,860 Underlying: Common Stock · 229,860 shares Expires 2035-09-09 F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 26,893 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024443 · form4-09122025_060903.xml · derivative · entry 2 Soffer Gad · CIK 0001612090 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,893 Underlying: Common Stock · 26,893 shares Expires 2035-02-10 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 26,893 | Not disclosed Strike: $41.84 | Not disclosed |
DisclosureSEC source: 0001415889-25-024443 · form4-09122025_060903.xml · derivative · entry 1 Soffer Gad · CIK 0001612090 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,893 shares Expires 2035-02-10 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 22, 2018 Filed Sep 25, 2018 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 22,158 | $39.85 | $882,996.30 |
DisclosureSEC source: 0001209191-18-052145 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,966 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 382 | $35.90 | $13,713.80 |
DisclosureSEC source: 0001209191-18-047221 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,124 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 382 | $45.90 | $17,533.80 |
DisclosureSEC source: 0001209191-18-030725 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,506 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 2,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011667 · doc4.xml · derivative · entry 3 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: Fully vested. F5 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 1,456 | $47.05 | $68,504.80 |
DisclosureSEC source: 0001209191-18-011667 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,888 F2 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 2,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011667 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 20:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,169 | $41.70 | $173,847.30 |
DisclosureSEC source: 0001209191-18-009406 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,580 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-18-008511 · doc4.xml · derivative · entry 3 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2025-02-06 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 3,987 | $35.80 | $142,734.60 |
DisclosureSEC source: 0001209191-18-008511 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,749 F2 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008511 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,736 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 18:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $15.00 | $105,000.00 |
DisclosureSEC source: 0001209191-17-061621 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,236 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061621 · doc4.xml · derivative · entry 3 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,764 Underlying: Common Stock · 4,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061621 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 17:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,464 | $14.53 | $35,801.92 |
DisclosureSEC source: 0001209191-17-049451 · doc4.xml · nonDerivative · entry 3 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,090 F3 · kind: Shares sold to cover tax liability from settlement of RSUs. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.30 to $14.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 4,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049451 · doc4.xml · derivative · entry 4 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,910 Underlying: Common Stock · 4,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049451 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $15.00 | $105,000.00 |
DisclosureSEC source: 0001209191-17-049451 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,409 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. Read SEC document |
| May 16, 2017 Filed May 17, 2017 16:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,674 | $15.19 | $86,188.06 |
DisclosureSEC source: 0001209191-17-033185 · doc4.xml · nonDerivative · entry 4 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,409 F4 · kind: Shares sold to cover tax liability from settlement of RSUs. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033185 · doc4.xml · derivative · entry 6 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,055 Underlying: Common Stock · 4,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F9 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F10 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 6,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033185 · doc4.xml · derivative · entry 5 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 25, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) March 13, 2020 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033185 · doc4.xml · nonDerivative · entry 3 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 6,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033185 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $15.13 | $105,910.00 |
DisclosureSEC source: 0001209191-17-033185 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,527 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 17:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0001209191-17-020262 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,527 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,273 | $15.62 | $113,604.26 |
DisclosureSEC source: 0001209191-17-011766 · doc4.xml · nonDerivative · entry 4 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,027 F4 · kind: Shares sold to cover tax liability from settlement of RSUs. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.40 to $16.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011766 · doc4.xml · derivative · entry 6 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,201 Underlying: Common Stock · 4,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F9 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F10 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 9,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011766 · doc4.xml · derivative · entry 5 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 Underlying: Common Stock · 9,616 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 25, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) March 13, 2020 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011766 · doc4.xml · nonDerivative · entry 3 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 9,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011766 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $15.22 | $106,540.00 |
DisclosureSEC source: 0001209191-17-011766 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,538 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 18:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $16.13 | $6,452.00 |
DisclosureSEC source: 0001209191-17-010165 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,538 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F2 · kind: Shares sold to cover tax liability from settlement of RSUs. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.00 to $16.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 18:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,874 | $15.42 | $90,577.08 |
DisclosureSEC source: 0001209191-17-010165 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,938 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F2 · kind: Shares sold to cover tax liability from settlement of RSUs. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008824 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,812 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 17:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,480 | $18.41 | $27,246.80 |
DisclosureSEC source: 0001209191-16-151759 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,812 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.10 to $18.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 16, 2016 Filed Nov 16, 2016 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,136 | $19.27 | $137,510.72 |
DisclosureSEC source: 0001209191-16-150727 · doc4.xml · nonDerivative · entry 4 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,292 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F4 · kind: Shares sold to cover tax liability from settlement of RSUs. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.80 to $19.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150727 · doc4.xml · derivative · entry 6 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,347 Underlying: Common Stock · 4,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F9 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F10 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 9,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150727 · doc4.xml · derivative · entry 5 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,026 Underlying: Common Stock · 9,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 25, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) March 13, 2020 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150727 · doc4.xml · nonDerivative · entry 3 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 9,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150727 · doc4.xml · nonDerivative · entry 2 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,582 | $20.55 | $196,910.10 |
DisclosureSEC source: 0001209191-16-150727 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,667 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.15 to $21.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 19:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142707 · doc4.xml · nonDerivative · entry 1 Soffer Gad · CIK 0001612090 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,249 F1 · shares: These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.